Last reviewed · How we verify
AZD2811
AZD2811 is a small molecule that targets the S1P1 receptor.
AZD2811 is a small molecule that targets the S1P1 receptor. Used for Relapsing forms of multiple sclerosis.
At a glance
| Generic name | AZD2811 |
|---|---|
| Also known as | AZD1152 hQPA, AZD1152 hydroxyl-quinazoline pyrazole anilide |
| Sponsor | AstraZeneca |
| Drug class | S1P1 receptor modulator |
| Target | S1P1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
AZD2811 works by selectively binding to the sphingosine-1-phosphate receptor 1 (S1P1), which is involved in the regulation of lymphocyte trafficking and immune responses. This mechanism of action is thought to contribute to its therapeutic effects in various diseases.
Approved indications
- Relapsing forms of multiple sclerosis
Common side effects
- Nausea
- Headache
- Diarrhea
Key clinical trials
- Study of AZD2811 + Durvalumab in ES-SCLC (PHASE2)
- Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants. (PHASE1)
- AZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung Cancer (PHASE2)
- A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors. (PHASE1)
- AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3] (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD2811 CI brief — competitive landscape report
- AZD2811 updates RSS · CI watch RSS
- AstraZeneca portfolio CI